Deinove (DEINO)

Business description

Deinove is a biotech company that discovers, develops and manufactures compounds of industrial interest stemming from rare bacteria and intended for the health, nutrition and beauty markets.

Stock data

Market cap.€20.4m
Last close€1.92
High / Low (52 weeks)€3.6 / €1.8
Stock market listingAL
Forecast net debt (€m)5
Forecast gearing ratio (%)1622
SectorAlternative Energy

Price performance

Relative *(5.1)(7.3)(55.4)

* % Relative to local index

Other companies in sector Show

Company news

DEINOVE and ARBIOM join forces to develop a "carbon-free" chemical industry

Mon, 14 Mar 2016 18:00:00 GMT

Deinove SA (ALDEI) Declined -3.12% on Sep 12

Tue, 12 Sep 2017 11:48:45 GMT

Deinove SA (ALDEI) Dips -1.01% on Sep 17

Sun, 17 Sep 2017 11:37:30 GMT

Deinove SA (ALDEI) Move Up 1.04% on Sep 22

Fri, 22 Sep 2017 13:53:43 GMT

The Digest's 2015 6-Minute Country Guide to France's Advanced Bioeconomy

Wed, 16 Sep 2015 08:01:35 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2015A 0.5 (7.3) (7.3) (66.8) N/A N/A
2016A 0.8 (7.0) (6.9) (64.6) N/A N/A
2017E 0.5 (7.2) (8.0) (62.9) N/A N/A
2018E 2.6 (5.1) (5.9) (31.2) N/A N/A

Last updated on 01/09/2017

Investment summary

Deinove has selected key markets of interest, identified strains from its library of bacteria, which indicate suitability for commercial deployment, and formed partnerships to expedite that process. While uncertainties remain, commercial revenues are expected in 2018 and development of revenues in line with our projections would indicate a potential valuation of €4.4/share.

Last updated on 01/09/2017

Industry outlook

Environmentalism will continue to underpin growth in green chemistry, and the growing antimicrobial resistance to current antibiotics will demand the discovery of new antibiotic structures.

Last updated on 03/08/2017

Key management

Dr Philippe Pouletty, Chairman
Emmanuel Petiot, CEO
Julien Coste, CFO

Company address

22 rue Leon Jouhaux
75010 Paris
01 42 03 27 37
View website